Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • gastic cancer

    - PMLiVE

    Amgen agrees to lower prescription drug costs in deal with US government

    The company has invested $40bn in US R&D and manufacturing in the past seven years

    - PMLiVE

    Amgen reports positive results from landmark cardiovascular study

    The study found significant reductions of major cardiovascular events in high-risk adults following treatment

    - PMLiVE

    Amgen commits $650m to US manufacturing expansion

    The investment is expected to generate up to 750 new jobs

    - PMLiVE

    Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

    The phase 3 study included around 2,600 patients

    - PMLiVE

    Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

    Almost one million new cases of gastric cancer are diagnosed globally every year

    - PMLiVE

    Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD

    Immunoglobulin G4-related disease affects approximately 20,000 people in the US

    - PMLiVE

    Amgen’s Uplizna shows promise in phase 3 generalised myasthenia gravis study

    Regulatory submissions are expected to be complete in the first half of this year

    - PMLiVE

    Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis

    The inflammatory skin disease affects up to 20% of children and 10% of adults worldwide

    - PMLiVE

    Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

    Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

    - PMLiVE

    Amgen’s Blincyto granted EC approval for new acute lymphoblastic leukaemia indication

    B-ALL is the most common form of the blood cancer, accounting for approximately 75% of adult cases

    - PMLiVE

    Amgen’s Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer

    The combination therapy has been authorised for use in adults harbouring KRAS G12C mutations

    - PMLiVE

    Amgen’s Imdylltra approved by MHRA to treat small cell lung cancer in adults

    SCLC accounts for approximately 15% of all lung cancer diagnoses and progresses rapidly

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links